松弛素对TGF-β诱导的内皮细胞间质化的抑制作用

摘要
图/表
参考文献
相关文章 (2)

全文: PDF (922 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨松弛素（RLX）对TGF-β诱导的内皮细胞间质化现象的影响。方法：采用体外分离的人脐静脉内皮细胞（HUVECs）作为体外细胞模型，通过TGF-β10 ng/mL诱导内皮细胞间质化，100 ng/mL和200 ng/mL RLX分别预处理，再与TGF-β联合培养48 h。光镜下观察细胞形态学改变，CCK-8实验和transwell实验检测细胞增殖和迁移能力，免疫荧光单双染技术观察vimentin和CD31的表达变化，蛋白免疫印迹技术观察各实验组vimentin、CD31、ve-cadherin和α-SMA的蛋白表达。结果：阴性对照组内皮细胞呈铺路石样生长，TGF-β诱导组细胞形态向梭形转化，呈扩散迁移趋势。与阴性对照组相比，TGF-β诱导组细胞增殖、迁移能力明显增强；而RLX可抑制TGF-β诱导的增殖和迁移。免疫荧光单染结果显示，与阴性对照组相比，TGF-β诱导组内皮细胞特异性蛋白CD31表达下调而间质细胞标志性蛋白vimentin明显上升；与TGF-β组相比，RLX联合TGF-β处理组CD31表达上调而vimentin表达下调。免疫荧光双染结果显示，阴性对照组以内皮性质的细胞为主，仅存在少量的CD31和vimentin双阳性细胞；TGF-β诱导组双阳性细胞明显增多；与TGF-β组相比，RLX联合TGF-β处理组间质效应的双阳性细胞下调，而内皮效应的双阳性细胞增多。蛋白免疫印迹结果显示，与阴性对照组相比，TGF-β诱导组内皮细胞特异性蛋白CD31（0.36±0.076 vs 0.88±0.086）和ve-cadherin（0.54±0.046 vs 1.09±0.13）表达下调而间质细胞标志性蛋白vimentin（0.72±0.102 vs 0.21±0.081）和α-SMA（0.88±0.084 vs 0.24±0.046）明显上升（P＜0.05）；与TGF-β组相比，RLX联合TGF-β处理组CD31（0.67±0.09、0.59±0.12 vs 0.36±0.076）和ve-cadherin（0.85±0.09、0.72±0.064 vs 0.54±0.046）表达上调，而vimentin（0.56±0.011、0.48±0.06 vs 0.72±0.102）和α-SMA（0.65±0.081、0.54±0.032 vs 0.88±0.084）表达下降（P＜0.05），且呈剂量依赖性。结论：RLX可抑制TGF-β诱导的内皮细胞向间质化细胞转化。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈潇1
	周浩1
	周希1
	蔡洁洁1
	陈灵芝2
	郑高暑1
	黄伟剑1
	张怀勤1

关键词 ：松弛素, 内皮细胞间质化, TGF-&beta, 心肌纤维化

Abstract：Objective: To investgate the effect of relaxin which inducing endothelial to mesenchymal transition in vitro. Methods: Endothelial cells were isolated from human umbilical vein endothelial cells (HUVECs). TGF-β10 ng/mL was added to medium for inducing endothelial to mesenchymal transition. Pretreatment relaxin 100 ng/mL and 200 ng/mL was added to medium, then co-cultured with TGF-β10 ng/mL for 48 h. The changes of morphology were observed under an inverted phase contrast microscope. CCK-8 assay was used to evaluate the cell proliferation as well as Transwell tested cell migration. The expression of CD31, vimentin, ve-cadherin andα-SMA were determined by immunofluoresence staining and western blot analysis. The co-expression of CD31 with vimentin and VWF withα-SMA were also determined by immunofluoresence. Results: A paving stone-like growth was observed in control group while TGF-βinduced more spreading and migrating cells which was called EMT. However, this transition could be prevented by relaxin. Compared with the control group, the proliferation and the mobility were increased by TGF-β(P<0.05), but declined when combining with relaxin compared to adding TGF-βonly (P<0.05). Compared with the control group, the specific protein of endothelial CD31 (0.36adding TGF-β, but the specific protein of mesenchymal vimentin (0.72±0.102 VS 0.21±0.081) and α-SMA(0.88±0.084 VS 0.24±0.046) were significantly increased. However, relaxin could inhibit the phenotype switch. Compared with the TGF-βinducing group, CD31 (0.67±0.09, 0.59±0.12 VS 0.36±0.076) and ve-cadherin(0.85±0.09, 0.72±0.064 VS 0.54±0.046) were significantly increased, but vimentin (0.56±0.011, 0.48±0.06 VS 0.72±0.102) andα-SMA (0.65±0.081, 0.54±0.032 VS 0.88±0.084) were significantly decreased when combining with relaxin. Besides, it exhibited dose-dependent. Last but not least, the number of double positive cells was largely increased in TGF-βinducing group compared to the control group. And compared with the TGF-β group, double positive cells performing mesenchymal are declined while performing endothelial ones are increased in the combined group. Conclusion: Relaxin exhibits the inhibition effect for TGF-βinduced endothelial to mesenchymal transition in vitro.

Key words： relaxin endothelial to mesenchymal transition TGF-β myocardial fibrosis

收稿日期: 2013-11-28

基金资助:浙江省自然科学基金资助项目（LY12H02004）

通讯作者: 张怀勤，主任医师，硕士生导师，Email：zhanghuaiqin@126.com。

作者简介: 陈潇（1987-），女，浙江宁波人，硕士生。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2014/V44/I3/161

[1] Zeisberg EM, Tarnavski O, Zeisberg M, et al. Endothelial to mesenchymal transition contributes to cardiac fibrosis[J].Nat Med, 2007, 13(8): 952-961.

[2] Sherwood OD. Relaxin physiological roles and other diverse actions[J]. Endocr Rev, 2004, 25(2): 205-234.

[3] Du XJ, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy[J].Nat Rev Cardiol, 2010, 7(1): 48-58.

[4] Roxburgh SA, Murphy M, Pollock CA, et al. Recapitulation of embryological programmes in renal fibrosis-the importance of epithelial cell plasticity and developmental genes [J]. Nephron Physiol, 2006, 103(3): 139-148.

[5] Kovacic JC, Mercader N, Torres M, et al. Epithelial to mesenchymal and endothelial to mesenchymal transition: from cardiovascular development to disease[J]. Circulation, 2012,125(14): 1795-1808.

[6] Xu J, Lamouille S, Derynck R. TGF-βinduced epithelial to mesenchymal transition[J]. Cell Res, 2009, 19(5): 156-172.

[7] Zhao L, Samuel CS, Tregear GW. Collagen studies in late pregnant relaxin null mice[J]. Biol Reprod, 2000, 63(3):697-703.

[8] Du XJ, Samuel CS, Gao XM, et al. Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype[J]. Cardiovasc Res,2003, 57(2): 395-404.

[9] Bathgate RA, Lekgabe ED, McGuane JT, et al. Adenovirus- mediated delivery of relaxin reverses cardiac fibrosis[J]. Mol Cell Endocrinol, 2008, 280(2): 30-38.

[10] Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo controlled, paral-lel group, dose-finding phase IIb study[J]. Lancet, 2009,373(9673): 1429-1439.

[11] 简宇, 黄宏, 简华刚. 内皮细胞-间质细胞转化在纤维化疾病中作用的研究进展[J]. 感染、炎症、修复, 2010, 11(3):179-181.